
PHAR
Pharming Group NV
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
10.1915
Open
10.1915
VWAP
10.19
Vol
501.00
Mkt Cap
6.98B
Low
10.1915
Amount
5.11K
EV/EBITDA(TTM)
33.10
Total Shares
67.34M
EV
710.71M
EV/OCF(TTM)
256.76
P/S(TTM)
2.03
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Show More
1 Analyst Rating

263.05% Upside
Wall Street analysts forecast PHAR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHAR is 37.00 USD with a low forecast of 37.00 USD and a high forecast of 37.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy

263.05% Upside
Current: 10.191

Low
37.00
Averages
37.00
High
37.00

263.05% Upside
Current: 10.191

Low
37.00
Averages
37.00
High
37.00
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$37
2025-03-21
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$37
2025-03-21
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$37
2025-03-20
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$37
2025-03-20
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$37
2025-03-14
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$37
2025-03-14
Reiterates
Strong Buy
Reason
Oppenheimer
Michael Carrier
Buy
Maintains
$30 → $39
2025-03-14
Reason
Oppenheimer
Michael Carrier
Price Target
$30 → $39
2025-03-14
Maintains
Buy
Reason
Oppenheimer raised the firm's price target on Pharming to $39 from $30 and keeps an Outperform rating on the shares following quarterly results. The firm notes 2024 revenue of $297M came in above its/consensus' estimates of $289/262M, as well as prior top-end guidance of $295M. Addition of KL1333 to the portfolio contributes the majority of the $9 added to the firm's new price target.
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$37
2024-12-17
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$37
2024-12-17
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$37
2024-12-16
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$37
2024-12-16
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Pharming Group NV (PHAR.O) is -262.34, compared to its 5-year average forward P/E of -90.98. For a more detailed relative valuation and DCF analysis to assess Pharming Group NV 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-90.98
Current PE
-262.34
Overvalued PE
131.67
Undervalued PE
-313.63
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
140.71
Current EV/EBITDA
205.15
Overvalued EV/EBITDA
401.25
Undervalued EV/EBITDA
-119.83
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued
5Y Average PS
2.84
Current PS
2.08
Overvalued PS
3.51
Undervalued PS
2.18
Financials
Annual
Quarterly
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
1
8.7K
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
PHAR News & Events
Events Timeline
2025-04-23 (ET)
2025-04-23
10:50:12
Pharming announces positive recommendation from NICE for Joenja

2025-01-21 (ET)
2025-01-21
16:22:10
Pharming to nominate Fabrice Chouraqui as new CEO, succeeding Sijmen de Vries

2024-12-15 (ET)
2024-12-15
15:34:36
Pharming announces public cash offer to shareholders of Abliva AB

Sign Up For More Events
Sign Up For More Events
News
9.5
07-17NewsfilterPharming Group to report second quarter and first half 2025 financial results and provide business update on July 31
1.0
06-24NewsfilterPharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis
5.0
06-11Yahoo FinancePharming Group reports on results of the 2025 Annual General Meeting of Shareholders
Sign Up For More News
People Also Watch

UFCS
United Fire Group Inc
27.130
USD
+0.86%

SMP
Standard Motor Products Inc
32.840
USD
-0.39%

NEXN
Nexxen International Ltd
11.090
USD
+0.73%

ZIP
Ziprecruiter Inc
4.480
USD
-2.40%

ORC
Orchid Island Capital Inc
7.320
USD
+0.27%

SVM
Silvercorp Metals Inc
4.725
USD
-0.94%

THRY
Thryv Holdings Inc
11.930
USD
+1.45%

BYRN
Byrna Technologies Inc
23.923
USD
+1.63%

ORIC
Oric Pharmaceuticals Inc
11.380
USD
-2.98%

EZPW
EZCORP Inc
13.490
USD
-0.07%
FAQ

What is Pharming Group NV (PHAR) stock price today?
The current price of PHAR is 10.1915 USD — it has increased 0 % in the last trading day.

What is Pharming Group NV (PHAR)'s business?

What is the price predicton of PHAR Stock?

What is Pharming Group NV (PHAR)'s revenue for the last quarter?

What is Pharming Group NV (PHAR)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Pharming Group NV (PHAR)'s fundamentals?

How many employees does Pharming Group NV (PHAR). have?
